Summary
CTLT Chart
Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus
Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract drugmaker Catalent over five years, a senior partner at the investment firm said, as it prepares for a likely focus on U.S. manufacturing by President-elect Donald Trump.
Novo Holdings completes $16.5 bln takeover of Catalent
Novo Holdings has completed its $16.5 billion takeover of Catalent , the contract drug manufacturer announced on Wednesday, days after the companies said all regulatory closing conditions were fulfilled.
Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say
All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding that the transaction is expected to be completed in the coming days.
Catalent Inc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| NA Nizar Araji National Bank Of Canada /FI/ | 15,260 | $1,954 | $1,954 | - | - |
| JM John Malone Amundi | 341,836 | $36,959 | $36,959 | - | - |
Catalent Inc (CTLT) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Catalent Inc Profile
| - Industry | - Sector | Mr. Alessandro Maselli CEO | NYSE Exchange | 148806102 CUSIP |
| United States Country | 17,000 Employees | - Last Dividend | - Last Split | 31 Jul 2014 IPO Date |
Overview
Catalent, Inc. is a global leader in delivering innovative solutions for drug development, biologic therapeutics, and consumer health products. With its foundation dating back to 1933, Catalent prides itself on its comprehensive expertise in advancing molecules, biologics, and consumer health products from early development to full-scale production. The company operates through two main segments: Biologics, and Pharma and Consumer Health, providing a broad spectrum of services worldwide. Catalent is committed to serving the pharmaceutical, biotechnology, consumer health, animal health, medical devices, and cosmetics industries. Headquartered in Somerset, New Jersey, Catalent stands as a pivotal partner for companies in various healthcare sectors, facilitating the pathway from laboratory to market.
Products and Services
Biologics Segment Services:
- Biologic Protein, Cell, and Gene Therapy Development: Offers formulation, development, and manufacturing services for a broad range of therapeutics including biologic proteins, cell gene therapies, pDNA, iPSCs, oncolytic viruses, and vaccines.
- Parenteral Dose Forms Manufacturing: Specializes in formulation, development, and manufacturing for parenteral dose forms such as vials, prefilled syringes, and cartridges.
- Large Molecule Analytical Development and Testing: Provides analytical development and testing services, focusing on large molecules.
Pharma and Consumer Health Segment Services:
- Soft Capsule Development and Manufacturing: Offers formulation, development, and manufacturing services for soft capsules utilized in prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
- Diverse Dose Forms Development and Manufacturing: Provides services for the development and manufacturing of oral, nasal, inhaled, and topical dose forms.
- Clinical Supply Services: Offers manufacturing, packaging, storage, distribution, and inventory management for clinical trials, covering small-molecule drugs, protein-based biologics, and cell and gene therapies.
- Pre-Clinical and Commercial Scale Manufacturing: Supplies pre-clinical screening, formulation, analytical development, and cGMP manufacturing services for a variety of formats including softgel capsules, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices.
Additional Services and Solutions:
- Direct-to-Patient and Demand-Led Clinical Supply Solutions: Catalent offers FlexDirect and FastChain services for innovative and flexible clinical supply and distribution.
- Fill and Finish Operations for Injectables: Provides specialized fill and finish operations for injectable products, ensuring quality and efficiency in the final stages of pharmaceutical manufacturing.
- Integrated Development and Supply Chain Solutions: Offers comprehensive solutions that streamline the product development lifecycle, from development through to supply chain optimization.
